Lung Cancer
Web Exclusives | May 16, 2023
A recently published case study found sotorasib efficacious and safe as first-line therapy for non–small cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | May 16, 2023
A Canadian study found that next-generation sequencing identified more mutations, had a faster turnaround time, and was more cost-effective than single-gene testing when used in patients with non–small cell lung cancer.
Web Exclusives | May 16, 2023
A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.
Web Exclusives | May 16, 2023
A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | April 19, 2023
A recent study demonstrates liquid biopsy has high concordance to tissue biopsy in non–small-cell lung cancer, making it an acceptable first-line testing option.
Sotorasib Found to Have Promising Intracranial Activity in Patients with NSCLC with Brain Metastasis
Web Exclusives | April 19, 2023
A small study of patients with non–small-cell lung cancer with brain metastasis showed sotorasib had promising efficacy on brain lesions.
Web Exclusives | April 19, 2023
A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes.
Web Exclusives | April 19, 2023
A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab.
Web Exclusives | March 15, 2023
Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.
Web Exclusives | March 15, 2023
A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.
© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512